| Citation: |
KE Chunjin, HU Zhiquan, YUE Daoyuan, SHEN Yuanqing, GAN Jiahua, TIAN Jihua, LI Song, LI Le, YANG Chunguang. Application of Tumor Markers in Patients with Urachal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(9): 676-679. DOI: 10.3971/j.issn.1000-8578.2020.20.0161
|
To analyze the expression of CEA, CA199 and CA724 in patients with urachal carcinoma, and to explore their correlation with disease diagnosis, staging, progression and treatment response.
Twelve urachal carcinoma patients with related tumor markers were selected as the research object and further divided into distant metastasis group (n=4) and non-metastasis group (n=8). We selected 40 patients with urothelial carcinoma of the bladder and 40 healthy people as the control groups. SPSS 23.0 and MedCalc 19 were used for data analysis.
Twelve patients with urachal carcinoma were all adenocarcinomas. The expression of CEA in the urachal carcinoma group was significantly higher than that in urothelial carcinoma group and healthy control group (P=0.01). The positive rate of CA724 in the distant metastasis group was significantly higher than that in the non-metastasis group (75% vs. 0, P=0.018). In single test, CEA diagnosed urachal carcinoma with the highest AUC of 0.750 and 95%CI of 0.584 to 0.916. The AUC detected by the combination of both CEA and CA724 or three tumor markers were all larger than the AUC detected by single test, but without statistical significance (0.817 vs. 0.805, P=0.8509).
The expression of CEA in patients with urachal carcinoma is significantly increased. CA724 can be used as a predictor of distant metastasis of urachal carcinoma, and the combination detection of CA724 and CEA can provide an effective reference for the clinical diagnosis of urachal cancer.
| [1] |
Wilcox DT, Godbole PP, Koyle MA. Pediatric urology: Surgical complications and management[M]. BK: Blackwell Publishing Ltd, 2008: 92-97.
|
| [2] |
Scabini S, Rimini E, Romairone E, et al. Urachal tumour: case report of a poorly understood carcinoma[J]. World J Surg Oncol, 2009, 7: 82. doi: 10.1186/1477-7819-7-82
|
| [3] |
Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation[J]. Am J Surg Pathol, 2009, 33(5): 659-668. doi: 10.1097/PAS.0b013e31819aa4ae
|
| [4] |
Johnson DE, Hodge GB, Abdul-Karim FW, et al. Urachal carcinoma[J]. Urology, 1985, 26(3): 218-221. doi: 10.1016/0090-4295(85)90112-8
|
| [5] |
牛海涛, 董平, 王佳妮, 等.手术后脐尿管癌的治疗及预后分析[J].中华医学杂志, 2016, 96(24): 1923-1925. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201624011
Niu HT, Dong P, Wang JN, et al. Analysis of treatment and prognosis in post-operative patients with urachal carcinoma[J]. Zhonghua Yi Xue Za Zhi, 2016, 96(24): 1923-1925. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201624011
|
| [6] |
Szarvas T, Módos O, Niedworok C, et al. ClinicaI, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1010 cases[J]. Urol Oncol, 2016, 34(9): 388-398. doi: 10.1016/j.urolonc.2016.04.012
|
| [7] |
魏玮, 王艺, 杨旭光. CA19-9、CEA对不同CRP水平晚期胰腺癌患者预后判断的临床价值[J].中华胰腺病杂志, 2018, 18(6): 384-388. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=yxbx201806007
Wei W, Wang Y, Yang XG. Clinical value of CA19-9 and CEA level in predicting the outcome of advanced pancreatic cancer patients with different C-reaction protein level[J]. Zhonghua Yi Xian Bing Za Zhi, 2018, 18(6): 384-388. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=yxbx201806007
|
| [8] |
叶进军, 辛乐, 刘继东, 等.血清微小RNA-183在结肠癌诊断中的价值[J].中华实验外科杂志, 2018, 35(10): 1937-1939. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsywk201810049
Ye JJ, Xin L, Liu JD, et al. Analysis on the value of serum microRNA-183 in the diagnosis of colon cancer[J]. Zhonghua Shi Yan Wai Ke Za Zhi, 2018, 35(10): 1937-1939. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsywk201810049
|
| [9] |
曹仲年, 郑容, 魏正茂, 等.肿瘤标志物和肺门淋巴结与肺腺癌全身骨显像骨转移的关系[J].肿瘤防治研究, 2019, 46(2): 149-152. doi: 10.3971/j.issn.1000-8578.2019.18.0703
Cao ZN, Zheng R, Wei ZM, et al. Relationship of Tumor Markers and Hilar Lymph Nodes with Bone Metastasis of Whole Body Bone Imaging in Lung Adenocarcinoma[J]. Zhong Liu Fang Zhi Yan Jiu, 2019, 46(2): 149-152. doi: 10.3971/j.issn.1000-8578.2019.18.0703
|
| [10] |
蔡晓娟, 王堃, 喻晶.异常凝血酶原联合CEA、CA72-4和CA199在胃癌诊治中的价值[J].肿瘤防治研究, 2018, 45(6): 395-399. doi: 10.3971/j.issn.1000-8578.2018.17.1007
Cai XJ, Wang K, Yu J. Clinical Value of Abnormal Prothrombin Combined with CEA, CA72-4 and CA199 on Patients with Gastric Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2018, 45(6): 395-399. doi: 10.3971/j.issn.1000-8578.2018.17.1007
|
| [11] |
Dhillon J, Liang Y, Kamat AM, et al. Urachal carcinoma:a pathologic and clinical study of 46 cases[J]. Human Pathol, 2015, 46(12): 1808-1814. doi: 10.1016/j.humpath.2015.07.021
|
| [12] |
Siefker-Radtke AO, Gee J, Shen Y, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience[J]. J Urol, 2003, 169(4): 1295-1298. doi: 10.1097/01.ju.0000054646.49381.01
|
| [13] |
Reis H, Krafft U, Niedworok C, et al. Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data[J]. Dis Markers, 2018, 2018: 7308168. http://europepmc.org/abstract/MED/29721106
|
| [14] |
Zong L, Chen P. Surgical and chemotherapeutic experience regarding a urachal carcinoma with repeated relapse: case report and literature review[J]. World J Surg Oncol, 2013, 11: 170. doi: 10.1186/1477-7819-11-170
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: